UCSF building

University of California, San Francisco (UCSF) is one of twenty-two Type 1 Diabetes TrialNet International Clinical Centers at the forefront of type 1 diabetes research. Led by Stephen Gitelman, MD, the TrialNet team at UCSF is dedicated to preventing type 1 diabetes and stopping disease progression by preserving insulin production before and after diagnosis.

Our Team

Portrait photo

Stephen Gitelman, MD

Portrait photo

Srinath Sanda, MD

Portrait photo

Christine Torok

Study Coordinator

Glenna Auerback

Study Coordinator
Portrait photo

Rebecca Wesch

Study Coordinator

Karen Ko

Clinical Research Coordinator

Lindsay Jacobsohn

Clinical Research Coordinator

"Our study participants are, by far, my favorite part of my job.  I love working with them and am in awe of everything that they handle every single day.  All participants manage their diabetes 24 hours a day, 7 days a week.  On top of that, they give of their time and energy to partake in one of our research studies.  Without them, there would be no TrialNet." – Christine Torok

Regional Affiliates

Affiliates provide opportunities for people who do not live near a TrialNet Clinical Center. The affiliate sites listed below work with UCSF to offer convenient participation in our research programs

Childrens Hospital Los Angeles
4650 Sunset Blvd. , Los Angeles, 90027 United States
Childrens Hospital and Research Center at Oakland
747 52nd St. , Oakland, 94609 United States
Scripps Whittier Diabetes Institute
9898 Genesee Ave., 6th Floor , La Jolla, 92037 United States
University of Arizona Pediatric Endocrinology
1501 N Campbell Ave , Tucson, 85724 United States
AMCR Institute, Inc.
625 West Citricado Pkwy Suite 112, Escondido, 92026 United States
Southern California Permanente Medical Group
3955 Bonita Road , Bonita, 91902 United States
University of Southern California
150 N. Robertson Blvd. Ste 210 , Beverly Hills, 90211 United States
White Memorial Medical Center
1720 Cesar E. Chavez Ave. , Los Angeles, 90033 United States
John Muir Physician Network Clinical Research Center
2700 Grant Street Suite 202 , Concord, 94520 United States
Phoenix Childrens Hospital
1919 E Thomas Road , Phoenix, 85016 United States
Palm Research Center, Inc
9280 W. Sunset Rd, Suite 306 , Las Vegas, 89148 United States
Touro University
1310 Club Drive , Vallejo, 94592 United States
SVMC Diabetes & Endocrine Center
355 Abbott St STE 200 , Salinas, 93901 United States
Pediatric Endocrinology and Diabetes Consultants
9900 Stockdale Hwy. #105 , Bakersfield, 93311 United States
University of California - Los Angeles
10833 le Conte Ave,22-315 MDCC , Los Angeles, 90095 United States
TMCOne Pediatric Endocrinology
2380 N, Ferguson Avenue,Suite 104 , Tucson, 85712 United States

Research Studies

Risk Screening Risk Screening for Relatives

If you have a relative with T1D, you may be eligible for risk screening that can detect the early stages of T1D years before symptoms appear. More

Monitoring Monitoring

Depending on your risk screening results, you may be eligible for monitoring. We’ll monitor you for disease progression and let you know if you become eligible for a study. More

Prevention Study ATG Prevention Study (STOP-T1D)

TrialNet is testing a low dose of the immunotherapy drug anti-thymocyte globulin (ATG) to see if it can delay or prevent type 1 diabetes (T1D) in people ages 12 up to 35 who have a 50% risk of clinical diagnosis (Stage 3) within 2 years. Risk is defined by having two or more autoantibodies and abnormal blood sugar (Stage 2), plus at least one high-risk marker (based on test results). In an earlier TrialNet study for people newly diagnosed with T1D, low-dose ATG preserved insulin production and improved blood sugar control for 2 years. Details

Newly Diagnosed JAK Inhibitors Newly Diagnosed Study (JAKPOT T1D)

TrialNet researchers are testing two different treatments – abrocitinib and ritlecitinib – to see if either or both can preserve insulin production in people (ages 12-35) newly diagnosed with type 1 diabetes (Stage 3 T1D). Abrocitinib and ritlecitinib are in a new class of autoimmune treatments called Janus kinase (JAK) inhibitors. Details

Newly Diagnosed Rituximab-pvvr / Abatacept Newly Diagnosed Study (T1D RELAY)

TrialNet is testing rituximab-pvvr and abatacept in people (ages 8-45) who were newly diagnosed with type 1 diabetes (T1D) to learn if using both treatments, one after the other, maintains the body’s ability to make insulin. By adding abatacept after rituximab-pvvr, researchers predict more people will experience prolonged beta cell function during and possibly after treatment. Details

Long Term Long-Term Follow-up

If you are diagnosed with T1D while participating in one of our prevention studies, we’re still here for you. You can continue to receive personal monitoring while helping us learn more. More

"The ultimate goal is to be able to screen and predict who is at risk for diabetes, and then have an efficient way to turn off the disease process, before T1D ever happens!"-Stephen Gitelman, MD, UCSF Principal Investigator